Abbott Laboratories (ABT)

RBC Wealth Management noted that the consensus 2026 earnings growth forecast for the S&P 500 saw an increase from 13.6% at the start of the year to 23.3% by the end of June.

TheFly reported on July 6 that Evercore ISI analyst Vijay Kumar reduced the firm’s price target on Abbott Laboratories to $112 from $120 while maintaining an Outperform rating on the shares.

The U.S. healthcare sector has lagged behind the entire market for three consecutive years, with returns of just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.

On May 10, Bloomberg reported that brain-computer interfaces are transitioning from experimental to early implementation, allowing users to control computers, robotic arms, and communication tools with...

The Fed's updated quarterly projections showed nine officials now anticipate a hike by the end of 2026, a sharp reversal from the cuts previously expected, and markets responded by pricing in better-than...

In May, Forbes reported that retail investors are continuing to put money into the market even as geopolitical tensions increase and market volatility edges higher.

On June 8, Reuters reported that Citigroup raised its 2026 year-end target for the S&P 500 index to more than 8,100, thanks to corporate earnings and ‌AI-driven growth.

Longevity stocks are getting more attention as investors look for companies tied to longer lifespans, healthier aging, and rising demand for care. The theme is broader than drugmakers.

Value stocks are on the move, after years of underperformance, amid heightened market volatility and a shift away from mega-cap concentration.